Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations

Željko Debeljak 1 , 2 , Sandra Dundović 3 , Sonja Badovinac 4 , Sanja Mandić 5 , 6 , Miroslav Samaržija 4 , 7 , Branko Dmitrović 5 , 6 , Marija Miloš 4 , Lana Maričić 5 , 6 , Vatroslav Šerić 5 , 6 ,  and Vikica Buljanović 3
  • 1 Institute of Clinical Laboratory Diagnostics, Osijek University Hospital, Josipa Huttlera 4, 31 000, Osijek, Croatia
  • 2 Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • 3 Našice General Hospital, Našice, Croatia
  • 4 University Hospital Center Zagreb, Zagreb, Croatia
  • 5 Osijek University Hospital, Osijek, Croatia
  • 6 Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • 7 School of Medicine, University of Zagreb, Zagreb, Croatia
Željko Debeljak
  • Corresponding author
  • Institute of Clinical Laboratory Diagnostics, Osijek University Hospital, Josipa Huttlera 4, 31 000, Osijek, Croatia
  • Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • Email
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Sandra Dundović, Sonja Badovinac, Sanja Mandić
  • Osijek University Hospital, Osijek, Croatia
  • Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Miroslav Samaržija
  • University Hospital Center Zagreb, Zagreb, Croatia
  • School of Medicine, University of Zagreb, Zagreb, Croatia
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Branko Dmitrović
  • Osijek University Hospital, Osijek, Croatia
  • Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Marija Miloš, Lana Maričić
  • Osijek University Hospital, Osijek, Croatia
  • Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • Search for other articles:
  • degruyter.comGoogle Scholar
, Vatroslav Šerić
  • Osijek University Hospital, Osijek, Croatia
  • Faculty of Medicine, University of Osijek, Cara Hadrijana 10, 31000, Osijek, Croatia
  • Search for other articles:
  • degruyter.comGoogle Scholar
and Vikica Buljanović

Abstract

Background:

Carbohydrate sulfotransferases (CHST) were shown to be involved in carcinogenesis. The aim of the study was to assess the diagnostic value of serum CHST7 concentration in differentiation between lung cancer and non-malignant pulmonary inflammations.

Methods:

Clinical case-control study involving 125 participants was conducted: the control group containing cases of pneumonia and chronic obstructive pulmonary disease was compared to the lung cancer group composed of primary and metastatic cancers. Serum concentrations of CHST7 and routinely used markers including carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (CYFRA 21-1) and neuron-specific enolase (NSE) were determined for each participant using immunochemical methods. Statistical association, receiver operating characteristic (ROC) analysis and cross-validation were used for the evaluation of CHST7 either as a standalone biomarker or as a part of a biomarker panel.

Results:

In comparison to the control group, serum CHST7 was elevated in lung cancer (p<0.001), but no differences between the overall stages of primary cancers were detected (p=0.828). The differentiation performance in terms of ROC area under curve (AUC) was 0.848 making CHST7 superior biomarker to the NSE (p=0.031). In comparison to CEA and CYFRA 21-1, the performance differences were not detected. CHST7 was not correlated to other biomarkers, and its addition to the routine biomarker panel significantly improved the cross-validated accuracy (85.6% vs. 75.2%) and ROC AUC (p=0.004) of the differentiation using a machine learning approach.

Conclusions:

Serum CHST7 is a promising biomarker for the differentiation between lung cancer and non-malignant pulmonary inflammations.

  • 1.

    Kitagawa H, Fujita M, Ito N, Sugahara K. Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase. J Biol Chem 2000;28:21075–80.

  • 2.

    Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, et al. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 2011;13:R58.

    • Crossref
    • Export Citation
  • 3.

    Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R. The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 2004;18:779–81.

    • Crossref
    • PubMed
    • Export Citation
  • 4.

    Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E, et al. Versican in non-small cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 2005;36:44–50.

    • Crossref
    • PubMed
    • Export Citation
  • 5.

    Ly M, Laremore TN, Linhardt RJ. Proteoglycomics: recent progress and future challenges. OMICS 2010;14:389–99.

    • Crossref
    • PubMed
    • Export Citation
  • 6.

    Stylianou M, Skandalis SS, Papadas TA, Mastronikolis NS, Theocharis DA, Papageorgakopoulou N, et al. Stage-related decorin and versican expression in human laryngeal cancer. Anticancer Res 2008;28:245–51.

    • PubMed
    • Export Citation
  • 7.

    Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, et al. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10:2491–8.

    • Crossref
    • PubMed
    • Export Citation
  • 8.

    Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008;18:288–95.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005;15:483–94.

    • Crossref
    • PubMed
    • Export Citation
  • 10.

    Ruffell B, Poon GF, Lee SS, Brown KL, Tjew SL, Cooper J, et al. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages. J Biol Chem 2011;286:19179–90.

    • Crossref
    • PubMed
    • Export Citation
  • 11.

    Pirinen R, Tammi R, Tammi M, Hirvikoski P, Parkkinen JJ, Johansson R, et al. Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int J Cancer 2001;95:12–7.

    • Crossref
    • PubMed
    • Export Citation
  • 12.

    Vachon E, Martin R, Plumb J, Kwok V, Vandivier RW, Glogauer M, et al. CD44 is a phagocytic receptor. Blood 2006;107:4149–58.

    • Crossref
    • PubMed
    • Export Citation
  • 13.

    Luo Z, Wu RR, Lv L, Li P, Zhang LY, Hao OL, et al. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 2014;7:3632–46.

    • PubMed
    • Export Citation
  • 14.

    Ween PM, Oehler KM, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011;12:1009–29.

    • Crossref
    • PubMed
    • Export Citation
  • 15.

    Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al. Gene expression profiling reveals novel biomarkers in non-small cell lung cancer. Int J Cancer 2011;129:355–64.

    • Crossref
    • PubMed
    • Export Citation
  • 16.

    Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010;5:e10312.

    • Crossref
    • PubMed
    • Export Citation
  • 17.

    Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009;69:9202–10.

    • Crossref
    • PubMed
    • Export Citation
  • 18.

    Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med 2008;2:577–86.

    • Crossref
    • PubMed
    • Export Citation
  • 19.

    Qi W, Li X, Kang J. Advances in the study of serum tumor markers of lung cancer. J Canc Res Ther 2014;10:95–101.

    • Crossref
    • Export Citation
  • 20.

    Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med 2015;13:55.

    • Crossref
    • PubMed
    • Export Citation
  • 21.

    Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer 2015;90:121–7.

    • Crossref
    • PubMed
    • Export Citation
  • 22.

    Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol 2014;5:660–6.

    • Crossref
    • PubMed
    • Export Citation
  • 23.

    Gonzalez J, Marin M, Sanchez-Salcedo P, Zulueta JJ. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med 2016;4:160.

    • Crossref
    • PubMed
    • Export Citation
  • 24.

    Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubientt SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009;101:554–9.

    • Crossref
    • PubMed
    • Export Citation
  • 25.

    Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J 2012;39:1230–40.

    • Crossref
    • PubMed
    • Export Citation
  • 26.

    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Brit J Cancer 2005;9:387–91.

  • 27.

    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem 2015;61: 1446–52.

    • Crossref
    • PubMed
    • Export Citation
  • 28.

    World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2194.

  • 29.

    Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243–60.

    • Crossref
    • PubMed
    • Export Citation
  • 30.

    Chheang S, Brown K. Lung cancer staging: clinical and radiologic perspectives. Semin Intervent Radiol 2013;30:99–113.

    • Crossref
    • PubMed
    • Export Citation
  • 31.

    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.

    • Crossref
    • PubMed
    • Export Citation
  • 32.

    Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.

    • Crossref
    • Export Citation
  • 33.

    Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2011;21:3940–1.

  • 34.

    Breiman L. Random forests. Mach Learn 2001;45:5–32.

  • 35.

    Liaw A, Wiener M. Classification and regression by random forest. R News 2002;2:18–22.

  • 36.

    R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2014.

  • 37.

    Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype and link to prognosis in human lung cancer. Am J Transl Res 2012;4:376–89.

    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Clinical Chemistry and Laboratory Medicine ( CCLM) publishes articles on novel teaching and training methods applicable to laboratory medicine. CCLM welcomes contributions on the progress in fundamental and applied research and cutting-edge clinical laboratory medicine. It is one of the leading journals in the field, with an impact factor of over three. CCLM is the official journal of nine national clinical societies and associated with EFLM.

Search